March 25, 2020 / 5:44 PM / 9 days ago

BRIEF-Gilead Says Submitted Request To FDA To Waive All Benefits That Accompany Orphan Drug Designation

March 25 (Reuters) - Gilead Sciences Inc:

* GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO RESCIND ORPHAN DRUG DESIGNATION GRANTED FOR INVESTIGATIONAL ANTIVIRAL FOR TREATMENT OF COVID19

* GILEAD SCIENCES SAYS SUBMITTED REQUEST TO U.S. FDA TO WAIVE ALL BENEFITS THAT ACCOMPANY THE ORPHAN DRUG DESIGNATION Source text : [ID:bit.ly/3dtO0lu] Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below